Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Panitumumab/ulixertinib

Acquired drug resistance and other toxicities: case report

    • 4 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Wang C, et al. A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors. Journal of Gastrointestinal Oncology 10: 1140-1143, No. 6, Dec 2019. Available from: URL: http://doi.org/10.21037/jgo.2019.08.02

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Panitumumab/ulixertinib. Reactions Weekly 1791, 206 (2020). https://doi.org/10.1007/s40278-020-75051-5

    Download citation